Abstract: A storage solution for packed red blood cells is disclosed where the solution is alkaline and has a viscosity at 4° C. greater than about 20 millipascal seconds. In one embodiment, the storage solution comprises from about 0.1 percent to about 10 percent of hydroxy-propyl-methyl-cellulose. In another embodiment, the storage solution has a pH greater than about 8.

Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.

Abstract: Solutions are provided herein for the collection of whole blood and/or storage of packed red blood cells, the solutions including one or more inorganic pyrophosphates (PPi). Also provided are methods of storing whole blood or packed red blood cells and methods of mitigating a complication associated with a transfusion or infusion of whole blood or red blood cells, the methods including storing the whole blood or red blood cells in a solution including one or more inorganic pyrophosphates.

Abstract: A method of immune phenotyping (evaluating adaptive and innate immune status) a subject is disclosed that includes providing a biological sample comprising diluted whole blood or isolated peripheral blood mononuclear cells (PBMCs), quantitating T cell interferon-gamma (IFN-?) and monocyte TNF-? production using ELISpot in the biological sample comprising diluted whole blood, and determining that the subject has an immunosuppressive immunological endotype if T cell interferon-gamma (IFN-?) and/or monocyte TNF-? production are decreased or low compared to a healthy subject. The disclosed method may be used to evaluating drug efficacy by measuring immune function in a subject after administering a drug to the subject to determine changes in the immune function of the subject in response to the drug.

Abstract: An electrical connection system can include a cage and/or a corresponding cable. The cage can be formed by walls and define faces on the top, bottom, right, left, front, and rear. A rear portion can house a receiving portion of a connector interface, which can be engaged via insertion of a module through the front face, or alternately by insertion of a plug through the top face. The cable at a terminating end can include the plug, which may include a vertical upright column and a horizontal base that includes an insertion portion of the connector interface. The cable at an originating end can include another instance of the receiving portion of the connector interface. A retainer can be provided to retain the plug in engagement with the receiving portion of the connector in the cage. The retainer can include a cover or other structure on the cable and/or cage.

Abstract: Digital image analysis can simultaneously measure many multidimensional features of each data point within an image. Each data point can then be grouped into categories, or ‘clusters’, of data points by assessing all features of each data point and measuring similarity among all data points. Clustering multidimensional data allows one to visualize the structure of their data and visually represent groups of data points in a lower dimensional space, such as a 2D or 3D graph. If the data points are not tagged with a description before clustering, it is difficult to assess which data points belong to which cluster. In this method, we describe the clustering of tissue objects (data points) into clusters based on their image analysis features, then creating a cluster map in order to describe tissue objects based on cluster association.

Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.

Abstract: An embodiment of the invention is a peptide comprising four domains, wherein domain I consists of thioctyl or monocytl, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit; and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. I. The peptide is preferably attached to a gold nanostructure, preferably a gold nanorod to provide an EFGR kit. An EFGR detection kit of the invention employs a gold nanostructure attached to a peptide sequence, the peptide sequence includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains activity of the binding sequence, and a unit that increases hydrophilicity of the peptide sequence.

Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavanoids-rich plant material that can be obtained from green tea. The EGCg is an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. Therapy and sensing methods are conducted with nanoparticles of the invention.

Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavonoids-rich plant material that can be obtained from green tea. The EGCg is an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. In preferred embodiment method of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with EGCg in a buffer, such as deionized water. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of EGCg. The thermodynamically feasible redox couple of AuCl4-/EGCg leading to the reduction of AuCl4- by EGCg to form gold nanoparticles. In another embodiment, pre-cooled gold salt and EGCg solutions form multi-layered EGCg coated particles.

Abstract: An embodiment of the invention is a peptide comprising four domains, wherein domain I consists of thioctyl or monocytl, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit; and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. I. The peptide is preferably attached to a gold nanostructure, preferably a gold nanorod to provide an EFGR kit. An EFGR detection kit of the invention employs a gold nanostructure attached to a peptide sequence, the peptide sequence includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains activity of the binding sequence, and a unit that increases hydrophilicity of the peptide sequence.

Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.

Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.

Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.

Abstract: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.

Abstract: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.

Abstract: This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.

Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.

Abstract: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.